Phase i study of sunitinib and erlotinib in advanced nonsquamous non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 6, Issue 5, 2011, Pages 951-953

  O'Mahar, Shannon E ^a   Campbell, Toby C ^a   Hoang, Tien ^a   Seo, Songwon ^a   Kim, Kyungmann ^a   Larson, Martha M ^a   Marcotte, Sarah M ^a   Loconte, Noelle K ^a   Traynor, Anne M ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Epidermal growth factor receptor; Non small cell lung cancer; Phase I clinical trial; Receptor protein tyrosine kinases; Vascular endothelial growth factor receptors

Indexed keywords

ERLOTINIB; SUNITINIB;

ABDOMINAL PAIN; ACNE; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; ILEUS; LEUKOPENIA; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

EID: 79955454505     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31820db227     Document Type: Article

References (15)

1. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132. (Pubitemid 41058344)
2. Novello S, Scagliotti GV, Rosell R, et al. Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. Br J Cancer 2009;101:1543-1548.
3. Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. J Clin Oncol 2008;26:650-656. (Pubitemid 351264362)
4. Naumov GN, Nilsson MB, Cascone T, et al. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 2009;15:3484-3494.
5. Ciardiello F, Bianco R, Caputo R, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004;10:784-793. (Pubitemid 38174017)
6. Kabbinavar F, Miller V, Johnson BE, et al. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B first-line treatment of locally advanced, recurrent, or metastatic nonsmall cell lung cancer (NSCLC). J Clin Oncol 2010;28:544s.
7. Herbst RS, Stern H, Amler L, et al. Biomarker evaluation in the phase III, placebo (P)-controlled, randomized beta trial of bevacizumab (B) and erlotinib (E) for patients (Pts) with advanced non-small cell lung cancer (NSCLC) after failure of standards 1st-line chemotherapy: correlation with treatment outcomes. J Thorac Oncol 2009;9:S323.
8. Natale RB, Bodkin D, Govindan R, et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. J Clin Oncol 2009;27:2523-2529.
9. Socinski MA. The current status and evolving role of sunitinib in non-small cell lung cancer. J Thorac Oncol 2008;3:S119-S123.
10. Ryan CW, Curti BD, Quinn DI, et al. A phase II study of sunitinib (S) plus erlotinib (E) in advanced renal carcinoma (RCC). J Clin Oncol 2010;28:348s.
11. Lind JS, Dingemans AM, Groen HJ, et al. A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer. Clin Cancer Res 2010;16:3078-3087.
12. Quintela-Fandino M, Le Tourneau C, Duran I, et al. Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. Mol Cancer Ther 2010;9:751-760.
13. Duran I, Hotte SJ, Hirte H, et al. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res 2007;13:4849-4857. (Pubitemid 47294792)
14. Kang SP, Ratain MJ. Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products. Clin Cancer Res 2010;16:4446-4451.
15. Scagliotti GV, Krzakowsi M, Szczesna A, et al. Sunitinib (SU) in combination with erlotinib (E) for the treatment of advanced/metastatic non-small cell lung cancer (NSCLC): a phase III study. Ann Oncol 2010;21:viii3.